Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2269683

Cc1ccc(NC(=O)Nc2cccc(CNc3c[nH]nc3C(N)=O)c2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.46
AURKA O14965 11/20 0.45
RPS6KB1 P23443 11/20 0.45
AURKB Q96GD4 7/20 0.45
HIF1A Q16665 4/20 0.44
KCNMA1 Q12791 1/20 0.42
PDPK1 O15530 1/20 0.42
DDR2 Q16832 1/20 0.41
TPSAB1 Q15661 1/20 0.41
JAK3 P52333 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3823534 0.94 PARP1 (0.50) PARP1AURKARPS6KB1AURKBHIF1A
Trifluoroacetic Acid SCHEMBL2267257 0.94 AURKA (0.52) PARP1AURKARPS6KB1AURKBKCNMA1
Trifluoroacetic Acid SCHEMBL2268948 0.92 PARP1 (0.45) PARP1AURKARPS6KB1AURKBHIF1A
Trifluoroacetic Acid SCHEMBL2266587 0.92 AURKA (0.54) PARP1AURKARPS6KB1AURKBHIF1A
Trifluoroacetic Acid SCHEMBL2269109 0.91 AURKA (0.45) PARP1AURKARPS6KB1AURKBKCNMA1
Trifluoroacetic Acid SCHEMBL2266500 0.91 HIF1A (0.52) PARP1AURKARPS6KB1AURKBHIF1A
Trifluoroacetic Acid SCHEMBL2267560 0.91 AURKA (0.49) PARP1AURKARPS6KB1AURKBKCNMA1
Trifluoroacetic Acid SCHEMBL2267555 0.91 PARP1 (0.47) PARP1AURKARPS6KB1AURKBHIF1A
Trifluoroacetic Acid SCHEMBL2265231 0.89 AURKA (0.46) PARP1AURKARPS6KB1AURKBKCNMA1
Trifluoroacetic Acid SCHEMBL2267723 0.89 PARP1 (0.48) PARP1AURKARPS6KB1AURKBPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989439-B2 Substituted pyrazoles, compositions containing these, method of production and use SANOFI-AVENTIS (FR) 2011-08-02 US claimed
US-20090291984-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE SANOFI-AVENTIS (FR) 2009-11-26 US claimed
US-8420824-B2 Substituted pyrazoles, compositions containing these, method of production and use SANOFI (FR) 2013-04-16 US disclosed
US-8410286-B2 Substituted pyrazoles, compositions containing these, method of production and use SANOFI-AVENTIS (FR) 2013-04-02 US disclosed
US-20110237801-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE SANOFI-AVENTIS (FR) 2011-09-29 US disclosed
US-20110237641-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE SANOFI-AVENTIS (FR) 2011-09-29 US disclosed
US-7989439-B2 Substituted pyrazoles, compositions containing these, method of production and use SANOFI-AVENTIS (FR) 2011-08-02 US disclosed
US-20090291984-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE SANOFI-AVENTIS (FR) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237801-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE ADORA3, ADORA2B, CYP4B1 PARP1 881/4885AURKA 693/4885RPS6KB1 422/4885
US-20090291984-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE CYP4B1, ADORA1, CYP1B1 PARP1 732/4885AURKA 719/4885RPS6KB1 310/4885
US-20110237641-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE ADORA3, ADORA2B, CYP4B1 PARP1 881/4885AURKA 693/4885RPS6KB1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.